Targeted Therapies Forum 2022: In this video, Dr. Chul Kim discusses how to treat the rare percentage of patients with EGFR+ disease who develop pneumonitis and can no longer take Erlotinib.
We thank our sponsors for this year’s support!#genentech Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech
For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.